Humacyte's ATEV Meets Phase 3 Superiority Endpoint for Dialysis Access in Women; Plans FDA BLA Filing

summarizeSummary

Humacyte reported positive Phase 3 clinical trial results for its ATEV product in female dialysis patients, meeting its primary superiority endpoint and showing reduced infections, with plans to file a supplemental BLA with the FDA.

check_boxKey Events

• ATEV Meets Primary Endpoint

  The acellular tissue engineered vessel (ATEV) met the primary superiority endpoint in the V012 Phase 3 study for arteriovenous access in female patients requiring hemodialysis.

• Superior Catheter-Free Days

  ATEV patients experienced an average of 91 more catheter-free days compared to autologous arteriovenous (AV) fistula, the current standard of care (p=0.00070).

• Reduced Infections

  ATEV patients incurred 17 fewer dialysis access infections per 100 patient-years compared to AV fistula, demonstrating a favorable safety profile with no new or unexpected safety signals.

• Supplemental BLA Filing Planned

  Humacyte plans to file a supplemental Biologic License Application (BLA) with the FDA during the second half of 2026, targeting adult patients with end-stage kidney disease at increased risk of AV fistula maturation failure.

auto_awesomeAnalysis

Humacyte announced highly positive interim results from its Phase 3 clinical trial (V012) for its acellular tissue engineered vessel (ATEV) in female dialysis patients. The ATEV demonstrated superior catheter-free days and significantly fewer infections compared to the standard of care. This is a critical development for the company, which has recently faced financial challenges including a going concern warning and dilutive offerings. The successful trial outcome provides a strong positive signal for future product approval and commercialization, potentially addressing a significant unmet medical need and improving the company's long-term viability.